Bioavailability of Three Mitopure Formulations - Trial NCT06362018
Access comprehensive clinical trial information for NCT06362018 through Pure Global AI's free database. This phase not specified trial is sponsored by Amazentis SA and is currently Recruiting. The study focuses on Healthy Adults. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amazentis SA
Timeline & Enrollment
N/A
May 07, 2024
Jul 31, 2024
Primary Outcome
Plasma concentrations of Urolithin A over time and maximal plasma concentration (Cmax),Exposure to Urolithin A over time measured as area under the curve (AUC)
Summary
This study's design as an open-label, single-dose, randomized trial that aligns with the
 objective of characterizing the concentration-time profiles of three Urolithin A (Mitopure)
 formulations in a controlled setting. The inclusion criteria, stringent fasting requirements,
 standardized fluid intake and strict dietary restriction protocols ensure homogeneity among
 the study participants, enhancing the reliability of the outcomes.
 
 Ultimately, this clinical trial aims to contribute valuable insights into the pharmacokinetic
 behavior of the different Urolithin A formulations, facilitating informed decisions for
 future developments and applications in the realm of health and wellness.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06362018
Non-Device Trial